DrugPatentWatch Database Preview
IBANDRONATE SODIUM Drug Profile
or, see our see our flat-rate plans
When do Ibandronate Sodium patents expire, and what generic alternatives are available?
The generic ingredient in IBANDRONATE SODIUM is ibandronate sodium. There are sixteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the ibandronate sodium profile page.
Summary for IBANDRONATE SODIUM
| US Patents: | 0 |
| Applicants: | 13 |
| NDAs: | 15 |
| Suppliers / Packagers: | 13 |
| Bulk Api Vendors: | 132 |
| Clinical Trials: | 2,495 |
| Patent Applications: | 4,420 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for IBANDRONATE SODIUM |
| DailyMed Link: | IBANDRONATE SODIUM at DailyMed |
Pharmacology for IBANDRONATE SODIUM
| Ingredient-type | Diphosphonates |
| Drug Class | Bisphosphonate |
Synonyms for IBANDRONATE SODIUM
| (1-Hydroxy-3-(methyl(pentyl)amino)propane-1,1-diyl)diphosphonic acid |
| (1-Hydroxy-3-(methyl(pentyl)amino)propane-1,1-diyl)diphosphonicacid |
| (1-hydroxy-3-(methylpentylamino)propylidene)bisphosphonate |
| (1-Hydroxy-3-(methylpentylamino)propylidene)bisphosphonic acid sodium |
| (1-Hydroxy-3-(methylpentylamino)propylidene)bisphosphonic acid sodium hydrate |
| (1-Hydroxy-3-(methylpentylamino)propylidene)diphosphonic acid |
| [1 -Hydroxy-3-(methylpentylamino)-propylidene]bisphosphonic acid sodium salt |
| [1-Hydroxy-3- -propylidene]bisphosphonicacidsodiumsalt |
| [1-HYDROXY-3-(METHYL-PENTYL-AMINO)-1-PHOSPHONO-PROPYL]-PHOSPHONIC ACID |
| [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphono-propyl]phosphonic acid |
| [1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphonic acid |
| {1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid |
| 084I785 |
| 1-hydroxy-3-(methylpentylamino)propylidene bisphosphonic acid |
| 1-hydroxy-3-(methylpentylamino)propylidenebisphosphonate |
| 114084-78-5 |
| 138844-81-2 |
| 138926-19-9 |
| 23Y0B94E49 |
| 2467AH |
| AB0005104 |
| AB01275485-01 |
| ABP001087 |
| AC-521 |
| AC1L1U21 |
| AC1Q1W18 |
| AC1Q6RN2 |
| Acid ibandronico |
| ACT05524 |
| ACT05527 |
| AJ-77707 |
| AK120881 |
| AKOS015855723 |
| AKOS015994672 |
| AKOS025392160 |
| AKOS026750153 |
| AN-15797 |
| AN-31778 |
| AN-31785 |
| API0024527 |
| AS-12948 |
| BC219057 |
| BCP9000767 |
| BDBM12577 |
| BFQ |
| BG0654 |
| Bisphosphonate 2 |
| BM 21.0955 |
| BM 21.0955 . Na . H2O |
| BM 21.0955Na |
| BM 21.0955Na.H2O |
| BM 210955 |
| BM-21.0955 |
| BM-21.0955 monosodium salt monohydrate |
| BM-210955 |
| Bondenza |
| Bondronat |
| Bondronat (TN) |
| Boniva |
| Boniva (TN) |
| Bonviva |
| Bonviva (TN) |
| BRD-K08681769-323-01-1 |
| C9H22NO7P2.Na |
| C9H23NO7P2 |
| C9H24NNaO8P2 |
| CAS-138844-81-2 |
| CCG-213317 |
| CCG-220679 |
| CCG-222407 |
| CHEMBL1201008 |
| CHEMBL997 |
| CS-2725 |
| CS-2726 |
| CS-2727 |
| CT-064 |
| CTK8E7876 |
| CTK8E7877 |
| CTK8E7878 |
| D04486 |
| D08056 |
| D08SJZ |
| D0G9FL |
| DB00710 |
| Destara |
| DSSTox_CID_26618 |
| DSSTox_GSID_46618 |
| DSSTox_RID_81770 |
| DTXSID5048340 |
| DTXSID8046618 |
| EBD2156407 |
| FT-0602640 |
| FT-0627172 |
| GTPL3059 |
| H487 |
| HMS2090A13 |
| HMS3263M08 |
| HY-B0515 |
| HY-B0515A |
| HY-B0515B |
| Hydroxy-[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphinic acid sodium salt monohydrate |
| I14-0821 |
| Ibandronate |
| Ibandronate (Sodium Monohydrate) |
| Ibandronate (Sodium) |
| Ibandronate sodium (USAN) |
| Ibandronate sodium [USAN:JAN] |
| Ibandronate sodium hydrate |
| Ibandronate sodium hydrate (JAN) |
| Ibandronate sodium monohydrate |
| Ibandronate sodium salt |
| Ibandronate sodium salt monohydrate |
| Ibandronate sodium salt, >=97% (NMR), solid |
| Ibandronic Acid |
| Ibandronic acid (INN) |
| Ibandronic acid [INN:BAN] |
| Ibandronic acid monosodium salt monohydrate |
| Ibandronic acid Na salt |
| Ibandronic Acid Sodium Salt |
| ibandronic acid, sodium salt, monohydrate |
| J-003052 |
| J-007183 |
| J-007198 |
| J12U072QL0 |
| JMC515594 Compound 53 |
| K-4496 |
| KB-205162 |
| KS-00000IT5 |
| KS-000013JD |
| KS-1071 |
| LP01103 |
| LP058979 |
| LP068287 |
| LP071868 |
| LS-183991 |
| LS-186539 |
| LS-187361 |
| LXLBEOAZMZAZND-UHFFFAOYSA-M |
| M-1207 |
| MFCD07197214 |
| MolPort-023-219-579 |
| MolPort-023-222-355 |
| Monosodium [1-hydroxy-3-(methylpentylamino)propane-1,1-diyl]diphosphonate monohydrate |
| MPBVHIBUJCELCL-UHFFFAOYSA-N |
| NCGC00167428-01 |
| NCGC00261788-01 |
| Phosphonic acid, (1-hydroxy-3-(methylpentylamino)propylidene)bis- |
| Phosphonic acid, (1-hydroxy-3-(methylpentylamino)propylidene)bis-, monosodium salt |
| Phosphonic acid, (1-hydroxy-3-(methylpentylamino)propylidene)bis-, monosodium salt, monohydrate |
| Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene]bis- |
| R-484 |
| R484 |
| RG-484 |
| Ro-200-5450 |
| Roche brand of ibandronic acid, sodium salt, monohydrate |
| RPR 102289A |
| RPR-102289A |
| RT-013305 |
| RT-013306 |
| RTC-020914 |
| S0877 |
| SC-17206 |
| SCHEMBL1030768 |
| SCHEMBL1120210 |
| SCHEMBL9183 |
| sodium hydrate hydrogen {1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonate |
| SODIUM HYDRATE HYDROGEN 1-HYDROXY-3-[METHYL(PENTYL)AMINO]-1-PHOSPHONOPROPYLPHOSPHONATE |
| sodium hydrogen (1-hydroxy-3-(methyl(pentyl)amino)-1-phosphonopropyl)phosphonate |
| sodium hydrogen (1-hydroxy-3-(methyl(pentyl)amino)-1-phosphonopropyl)phosphonate hydrate |
| SODIUM HYDROGEN 1-HYDROXY-3-[METHYL(PENTYL)AMINO]-1-PHOSPHONOPROPYLPHOSPHONATE |
| sodium hydroxy-[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphono-propyl]phosphinate |
| sodium hydroxy-[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphono-propyl]phosphinate hydrate |
| Sodium Ibandronate |
| Sodium Trihydrogen (1-Hydroxy-3-(methylpenthylamino)propylidene)diphosphonate Monohydrate |
| Sodium trihydrogen (1-hydroxy-3-(methylpentylamino)propylidene)diphosphonate, monohydrate |
| sodium;hydroxy-[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphinate;hydrate |
| SodiumIbandronate |
| ST24026059 |
| TC-020914 |
| TL8000885 |
| Tox21_112432 |
| Tox21_501103 |
| UMD7G2653W |
| UNII-23Y0B94E49 |
| UNII-J12U072QL0 |
| UNII-UMD7G2653W |
| Z2181651281 |
| ZINC1533877 |
US Patents and Regulatory Information for IBANDRONATE SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accord Hlthcare | IBANDRONATE SODIUM | ibandronate sodium | INJECTABLE;INTRAVENOUS | 206058-001 | Feb 5, 2016 | AP | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Sun Pharm Inds Ltd | IBANDRONATE SODIUM | ibandronate sodium | INJECTABLE;INTRAVENOUS | 090853-001 | Feb 14, 2014 | AP | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Emcure Pharms Ltd | IBANDRONATE SODIUM | ibandronate sodium | INJECTABLE;INTRAVENOUS | 203987-001 | Sep 2, 2014 | AP | RX | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | |||
| Mylan Pharms Inc | IBANDRONATE SODIUM | ibandronate sodium | TABLET;ORAL | 078995-001 | Mar 19, 2012 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
or, see our see our flat-rate plans
or, see our see our flat-rate plans
